Affiliation:
1. Graduate School of Human and Environmental Studies Kyoto University Sakyo-ku 606-8501 Kyoto Japan
2. Innovation and Business Development Headquarters Daicel Corporation 1239, Shinzaike, Aboshi-ku 671-1283 Himeji Hyogo Japan
3. Institute for Integrated Radiation and Nuclear Science Kyoto University 2-1010, Asashiro-nishi, Kumatori-cho 590-0494 Sennan-gun Osaka Japan
Abstract
AbstractBoron neutron capture therapy (BNCT), advanced cancer treatment utilizing nuclear fission of 10B atom in cancer cells, is attracting increasing attention. As 10B delivery agent, sodium borocaptate (10BSH, 10B12H11SH ⋅ 2Na), has been used in clinical studies along with L‐boronophenylalanine. Recently, this boron cluster has been conjugated with lipids, polymers or nanoparticles to increase selectivity to and retentivity in tumor. In this work, anticancer nanoformulations for BNCT are designed, consisting of poly(glycerol) functionalized detonation nanodiamonds (DND−PG) as a hydrophilic nanocarrier, the boron cluster moiety (10B12H112−) as a dense boron‐10 source, and phenylboronic acid or RGD peptide as an active targeting moiety. Some hydroxy groups in PG were oxidized to carboxy groups (DND−PG−COOH) to conjugate the active targeting moiety. Some hydroxy groups in DND−PG−COOH were then transformed to azide to conjugate 10B12H112− through click chemistry. The nanodrugs were evaluated in vitro using B16 murine melanoma cells in terms of cell viability, BNCT efficacy and cellular uptake. As a result, the 10B12H112− moiety is found to facilitate cellular uptake probably due to its negative charge. Upon thermal neutron irradiation, the nanodrugs with 10B12H112− moiety exhibited good anticancer efficacies with slight differences with and without targeting moiety.
Subject
General Chemistry,Catalysis,Organic Chemistry
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献